Skip to main content
SpringerLink
Log in

Fortschritt in der Präzisionsonkologie

Sotorasib als mögliche neue zielgerichtete Therapie KRAS-G12C-mutierter Tumoren

  • Journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Cox AD et al. Nat Rev Drug Discov. 2014;13(11):828-51

  2. Canon J et al. Nature. 2019;575(7781):217-23

  3. Hong DS et al. N Engl J Med. 2020 Sep 24;383(13):1207-17

  4. LoRusso PM Sebolt-Leopold JS. N Engl J Med. 2020;383(13):1277-8

  5. https://adisinsight.springer.com/drugs/800052645 abgerufen am 16. März 2021

  6. https://adisinsight.springer.com/drugs/800056155 abgerufen am 16. März 2021

Download references

Author information

Authors and Affiliations

  1. Christian-Albrechts-Universität zu Kiel, Kiel, Deutschland

    Henrike Marnau &  Lea Spory

  2. Klinik f. Strahlentherapie, Campus Kiel, Arnold-Heller-Str. 3, 24105, Kiel, Deutschland

    Jürgen Dunst

Authors
  1. Henrike Marnau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lea Spory
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jürgen Dunst
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marnau, H., Spory, L. & Dunst, J. Sotorasib als mögliche neue zielgerichtete Therapie KRAS-G12C-mutierter Tumoren. InFo Hämatol Onkol 24, 33–35 (2021). https://doi.org/10.1007/s15004-021-8640-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8640-8

Search

Navigation